Pulmatrix, Inc.

Stage 4 · Declining · week 6

As of Oct 22, 2026, Pulmatrix is in Stage 4, the downtrend phase, now in week 6 (since Sep 15, 2026). It closed at $1.42, 71.3% below its 52-week high and below its 200-day average, which is falling.

$1.42

-9.55% today

$5.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PULM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S2 18w

S2 21w

S4 45w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 4w → S4 10w → S1 8w → S2 18w → S3 4w → S2 21w → S3 8w → S2 7w → S3 3w → S4 45w → S1 11w → S4 5w current

Total tracked: 166 weeks across 13 stage runs.

PULM among Biotechnology426th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…426	PULMPulmatrix, Inc.	Stage 4 · wk 6	15	−15.7%

vs 52W High

-71.3%

$1.19 lo$4.94 hi

71.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-18.2%

200 DMA: $1.74 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.91x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.7%

-13.9%

+1.4%

YTD

-37.2%

-71.3%

Scan Membership

Breakout Watch

Latest: 2025-06-10

6 appearances in last 60 days. First seen: 2020-01-14.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 0.91x

2026-10-21S4

Wk 6 · Vol 4.70x

2026-10-20S4

Wk 6 · Vol 0.50x

2026-10-19S4

Wk 5 · Vol 1.38x

2026-10-16S4

Wk 5 · Vol 0.56x

2026-10-15S4

Wk 5 · Vol 0.84x

2026-10-14S4

Wk 5 · Vol 0.38x

2026-10-13S4

Wk 5 · Vol 1.26x

2026-10-12S4

Wk 4 · Vol 0.33x

2026-10-09S4

Wk 4 · Vol 0.17x

2026-10-08S4

Wk 4 · Vol 0.50x

2026-10-07S4

Wk 4 · Vol 0.45x

Moving averages & range

50 DMA

$1.50

200 DMA

$1.74

52W High

$4.94

52W Low

$1.19

5D Low

$1.36

Resistance levels (recent highs)

20d High

$1.61

60d High

$1.74

120d High

$1.88

250d High

$4.94

Next resistance

+13.4%

to 20d High

ROE

-98.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.3

Pulmatrix: quick answers

What stage is Pulmatrix in?

As of Oct 22, 2026, Pulmatrix (PULM) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 15, 2026 and is in week 6. What the four stages mean

Is Pulmatrix in an uptrend?

No. Pulmatrix is in a Stage 4 downtrend. It trades 18.2% below its 200-day average, which is falling.

How far is Pulmatrix from its 52-week high?

Pulmatrix closed at $1.42 on Oct 22, 2026, 71.3% below its 52-week high of $4.94. Its 52-week low is $1.19.

How has Pulmatrix performed over the past year?

As of Oct 22, 2026, Pulmatrix is down 71.3% over the past year and down 37.2% so far in 2026.

Which sector and industry is Pulmatrix in?

Pulmatrix is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.